Health & MedicineBreaking NewsBreakingLatest News
Pioneering dementia trial will test diabetes and ADHD medicines against Alzheimer's
Sentiment: NeutralHigh Priority
What Happened?
A new dementia trial aims to halve the time for testing Alzheimer's treatments by evaluating multiple drugs at once. It will recruit 1,200 participants to test existing medications.
Key points
- The trial will evaluate ADHD drug atomoxetine and diabetes drug metformin.
- Participants will be randomly assigned to receive either a placebo or one of the two drugs.
- The study aims to recruit 1,200 people over four years, significantly more than previous trials.
- The trial is led by the UK Dementia Research Institute and Alzheimer’s Research UK.
- Atomoxetine targets noradrenaline, which is affected by Alzheimer’s disease.
- Metformin may lower dementia risk due to its effects on inflammation.
Key insights
- If successful, the trial could change how Alzheimer's treatments are developed and tested.
- The approach may encourage more pharmaceutical companies to participate in dementia research.
- Faster trials could lead to quicker availability of treatments for patients.
Why it matters
This trial could lead to faster access to effective treatments for Alzheimer's patients.
Entities
Imperial College London· OrganizationUK Dementia Research Institute· OrganizationAlzheimer’s Research UK· OrganizationAndy Burnham· PersonHeather Ransome· PersonRoy Burnham· PersonUK· Country
Source
Express
